# Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma

> **NCT00060684** · PHASE1 · COMPLETED · sponsor: **CTI BioPharma** · enrollment: 30 (—)

## Conditions studied

- Lymphoma, Low-Grade
- Lymphoma, Small Lymphocytic
- Lymphoma, Mixed-Cell, Follicular
- Lymphoma, Small Cleaved-Cell, Follicular

## Interventions

- **DRUG:** Pixantrone (BBR 2778)
- **DRUG:** fludarabine
- **DRUG:** dexamethasone
- **DRUG:** rituximab

## Key facts

- **NCT ID:** NCT00060684
- **Lead sponsor:** CTI BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-12
- **Primary completion:** 2005-01
- **Final completion:** 2007-05
- **Target enrollment:** 30 (—)
- **Last updated:** 2015-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00060684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00060684, "Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00060684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*